ACE-031: Preliminary Phase Ib data

Preliminary data from a double-blind, placebo-controlled Phase Ib trial in 60 healthy postmenopausal women showed that multiple-ascending doses of subcutaneous 0.1-3 mg/kg ACE-031 every 2 or 4 weeks f...